Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Crenshaw

Vascular Surgery Metairie, LA Medical Doctor

NPI 1326238171 CMS profile 332764

1 Galleria Blvd Ste 110, Metairie, LA 70001

Open in the dashboard

General payments

$66,905

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Crenshaw of Metairie, LA is reported in the CMS Open Payments database as having received $66,905 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,701 8
2024 General $18,001 6
2023 General $15,140 8
2022 General $2,648 46
2021 General $4,384 41
2020 General $186 8
2019 General $845 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Crenshaw
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Gregory Crenshaw were reported at $25,701. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Gregory Crenshaw Vascular Surgery median Middle half National median
2019 $845 $796 $226–$2,363 $163
2020 $186 $348 $118–$1,110 $114
2021 $4,384 $471 $158–$1,421 $132
2022 $2,648 $725 $222–$2,183 $149
2023 $15,140 $836 $257–$2,440 $160
2024 $18,001 $909 $252–$2,619 $164
2025 $25,701 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $56,559 17 payments
  2. Bard Peripheral Vascular, Inc. $3,575 14 payments
  3. Medtronic, Inc. $2,711 46 payments
  4. Janssen Pharmaceuticals, Inc $1,025 8 payments
  5. Philips Electronics North America Corporation $793 22 payments
  6. Biom'Up France SAS $570 4 payments
  7. Ethicon US, LLC $195 3 payments
  8. Cardiovascular Systems Inc. $156 5 payments
  9. Stryker Corporation $154 1 payment
  10. Dilon Technologies, Inc. $149 1 payment
  11. Other $1,018 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $56,278 4 payments
  2. Food and Beverage $5,395 127 payments
  3. Consulting Fee $4,050 2 payments
  4. Travel and Lodging $1,183 8 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $33,944 3 payments
  2. Auryon Laser System 100-120 Vac Cv $22,333 1 payment
  3. Ellipsys $2,014 22 payments
  4. XARELTO $1,025 8 payments
  5. HEMOBLAST BELLOWS $719 5 payments
  6. ELLIPSYS VASCULAR ACCESS SYSTEM $325 18 payments
  7. AURYON LASER SYSTEM 100-120 VAC Pad $231 11 payments
  8. Turbo Elite $228 5 payments
  9. (4067) Tack Endo Sys BTK $176 2 payments
  10. AVS ANCHOR-L $154 1 payment
  11. Other $2,323 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

95

Median for Vascular Surgery: 122

Drug cost

$7,577

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $7,020
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 58 $423
Clopidogrel Clopidogrel Bisulfate Brand 25 $134

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$312,138

Medicare's payments for the services billed

Medicare patients

211

Average age 67

Services billed

647

93 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 74%
Diabetes 63%
Arthritis 46%
Heart failure 45%
Ischemic heart disease 38%
COPD 27%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record